Cationic Adjuvant Formulation CAF®

Croda Pharma continuously increases its offering in innovative vaccine adjuvant systems. The strategic collaboration with SSI (Statens Serum Institut, leading Danish governmental life-science research institute) enables us to offer an even more diverse adjuvant portfolio. 

The CAF® technology platform is a range of new, patented, CMI inducing cationic liposomal adjuvants. Over the past decade, clinical trials have shown these to be powerful immunostimulators in tuberculosis, chlamydia, HIV, malaria, pandemic flu and specific cancer studies. 

Croda will manufacture and commercialise two CAF® adjuvants:

• CAF01 - a two component liposomal suspension which induces strong antibody and T-cell (Th1/Th17) responses in vaccines for infectious diseases. The potent neonatal adjuvanticity in preclinical studies suggests that it is fulfilling the requirements for novel vaccines to be used in early life
• CAF02 - a second generation, three component cationic liposomal adjuvant used in cancer immunotherapy trials, facilitating strong production of antigen specific CD8 + T-cells after vaccination in combination with peptide or protein-based antigens.